EV0.F · Evoke Pharma, Inc

-

Please sign in to comment on EV0.F

1 Comment

Admin

3 years, 7 months ago

Evoke Pharma, Inc is currently in a long term downtrend where the price is trading 53.0% below its 200 day moving average.

From a valuation standpoint, the stock is 63.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2145.2.

Evoke Pharma, Inc's total revenue rose by inf% to $23K since the same quarter in the previous year.

Its net income has dropped by 59.9% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 49.1% to $-2M since the same quarter in the previous year.

Based on the above factors, Evoke Pharma, Inc gets an overall score of 1/5.

Industry	Drug Manufacturers-Specialty & Generic
Sector	Healthcare
ISIN	None
CurrencyCode	EUR
Exchange	F

Target Price	9
PE Ratio	None
Market Cap	9M
Beta	0.74
Dividend Yield	0.0%

ABOUT

Evoke Pharma, Inc

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

EV0.F · Evoke Pharma, Inc

-

Evoke Pharma, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Evoke Pharma, Inc using a moving average strategy